CLINICAL STUDY: CORONARY ARTERY DISEASE
Enhanced detection of reversible perfusion defects by Tc-99m sestamibi compared to Tc-99m tetrofosmin during vasodilator stress SPECT imaging in mild-to-moderate coronary artery disease
Prem Soman, MD, PhD, MRCP*,
Raymond Taillefer, MD, FRCP(C) ,
E. Gordon DePuey, MD, FACC ,
James E. Udelson, MD, FACC and
Avijit Lahiri, MBBS, MSc, MRCP, FESC, FACC*
* Department of Cardiovascular Medicine, Northwick Park & St. Marks Hospitals, NHS Trust and Institute of Medical Research, Harrow, United Kingdom
Department of Nuclear Medicine, Hotel-Dieu De Montreal, Quebec, Canada
Division of Nuclear Medicine, St. Luke’s-Roosevelt Hospital Center, New York, New York, USA
Division of Cardiology, New England Medical Center, Boston, Massachusetts, USA
Manuscript received August 4, 1999;
revised manuscript received September 8, 2000,
accepted October 12, 2000.
Reprint requests and correspondence: Dr. Avijit Lahiri, Department of Cardiovascular Medicine, Northwick Park Hospital, Harrow, United Kingdom, HA1 3UJ
OBJECTIVES
We prospectively compared dipyridamole single-photon emission computed tomography (SPECT) imaging with Tc-99m sestamibi and Tc-99m tetrofosmin for the detection of reversible perfusion defects in patients with mild-to-moderate coronary artery disease.
BACKGROUND
Tc-99m tetrofosmin has a lower first-pass myocardial extraction fraction compared to Tc-99m sestamibi and thus could underestimate mild perfusion defects.
METHODS
Eighty-one patients with 50% to 90% stenosis in one or two major epicardial vessels without previous myocardial infarction, and seven with <5% probability of coronary artery disease underwent dipyridamole SPECT imaging with both agents. The SPECT data were analyzed quantitatively.
RESULTS
Tc-99m sestamibi detected reversible perfusion defects in a greater number of segments (total 363 and 285, p < 0.001, and mean ± SD, 2.2 ± 3.0 and 1.8 ± 2.5 per patient, p = 0.008, for Tc-99m sestamibi and Tc-99m tetrofosmin, respectively), demonstrated a larger extent of perfusion defect (mean ± SD, 15.8% ± 12.3% and 12.0% ± 11.4%, p < 0.03, for Tc-99m sestamibi and Tc-99m tetrofosmin, respectively) and more often correctly identified patients with disease in more than one coronary artery (p = 0.02). There was better defect contrast with Tc-99m sestamibi (defect/normal wall count ratios were 0.60 ± 0.15 vs. 0.73 ± 0.14 for Tc-99m sestamibi and Tc99m tetrofosmin, respectively, p = 0.01, for reversible defects seen in identical segments with both agents; and 0.73 ± 0.16 vs 0.79 ± 0.17, respectively, p <0.01, for reversible defects detected with either agent alone). There was no significant difference in diagnostic sensitivity or image quality.
CONCLUSIONS
These differences between two commonly used tracers may have significant diagnostic and prognostic implications.
|
Abbreviations and Acronyms
| | CAD | = coronary artery disease | | SPECT | = single-photon emission computed tomography |
|
This article has been cited by other articles:
|
|
|
|
 
I. Madar, H. Ravert, A. DiPaula, Y. Du, R. F. Dannals, and L. Becker
Assessment of Severity of Coronary Artery Stenosis in a Canine Model Using the PET Agent 18F-Fluorobenzyl Triphenyl Phosphonium: Comparison with 99mTc-Tetrofosmin
J. Nucl. Med.,
June 1, 2007;
48(6):
1021 - 1030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. DeLuca, E. Cusack, W. S. Aronow, and C. E. Monsen
Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value of the Dipyridamole Sestamibi Stress Test Comparing Arterial to Vein Conduits
Chest,
October 1, 2004;
126(4):
1040 - 1041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Y Loong and C Anagnostopoulos
Diagnosis of coronary artery disease by radionuclide myocardial perfusion imaging
Heart,
August 1, 2004;
90(suppl_5):
v2 - v9.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Borges-Neto, R. H. Tuttle, L. K. Shaw, W. T. Smith IV, D. Jain, R. E. Coleman, and D. Whellan
Outcome Prediction in Patients at High Risk for Coronary Artery Disease: Comparison between 99mTc Tetrofosmin and 99mTc Sestamibi
Radiology,
July 1, 2004;
232(1):
58 - 65.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Fleischmann, P. Koepfli, M. Namdar, C. A. Wyss, R. Jenni, and P. A. Kaufmann
Gated 99mTc-Tetrofosmin SPECT for Discriminating Infarct from Artifact in Fixed Myocardial Perfusion Defects
J. Nucl. Med.,
May 1, 2004;
45(5):
754 - 759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N K Sabharwal and A Lahiri
Role of myocardial perfusion imaging for risk stratification in suspected or known coronary artery disease
Heart,
November 1, 2003;
89(11):
1291 - 1297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Shaw, R. Hendel, S. Borges-Neto, M. S. Lauer, N. Alazraki, J. Burnette, E. Krawczynska, M. Cerqueira, and J. Maddahi
Prognostic Value of Normal Exercise and Adenosine 99mTc-Tetrofosmin SPECT Imaging: Results from the Multicenter Registry of 4,728 Patients
J. Nucl. Med.,
February 1, 2003;
44(2):
134 - 139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Elhendy, J. J. Bax, and D. Poldermans
Dobutamine Stress Myocardial Perfusion Imaging in Coronary Artery Disease
J. Nucl. Med.,
December 1, 2002;
43(12):
1634 - 1646.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F.L. Schinkel, A. Elhendy, R. T. van Domburg, J. J. Bax, J. R.T.C. Roelandt, and D. Poldermans
Prognostic Value of Dobutamine-Atropine Stress 99mTc-Tetrofosmin Myocardial Perfusion SPECT in Patients with Known or Suspected Coronary Artery Disease
J. Nucl. Med.,
June 1, 2002;
43(6):
767 - 772.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
